Adam Feuerstein

The biotech sector is turning profitable, reaching an inflection point that generalist investors will notice. 

The worst biopharma CEO of 2025? It's Sarepta Therapeutics' Doug Ingram, STAT's Adam Feuerstein says.

Best Biopharma CEOs of 2025, in @adamfeuerstein's view? There are quite a few.

A raging bull market for biotech stocks and a good story have transformed an ineffective weight loss drug into a Wall Street sensation.

This week on "The Readout LOUD": Is a new obesity drug making people lose too much weight? Plus catch up on #ASH25 and hear how the country's scientific institutions have had a bruising year.

Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology meeting.

Incyte's data bolster efforts to develop a new type of drug for myelofibrosis, and suggest it may be a replacement for Jakafi.

What to expect at the annual ASH conference, and some thoughts on FDA's Richard Pazdur.

On the new episode of "The Readout LOUD": a new top drug regulator, the future of psychedelics, and much more.